Journal: Advanced Healthcare Materials
Article Title: Repurposing FDA‐Approved Drugs for Temozolomide‐Resistant IDH1 Mutant Glioma Using High‐Throughput Miniaturized Screening on Droplet Microarray Chip
doi: 10.1002/adhm.202300591
Figure Lengend Snippet: Workflow for high‐throughput drug screening and hit validation. The droplet microarray chip uses minimal reagents (200 nL medium, 300 cells per spot) to screen 2208 FDA‐approved drugs rapidly and economically. The assay is validated using MTT assays in a standard 96‐well plate. On‐ and off‐target effects are assessed using Western blot and mass spectrometry. Drug target analysis is correlated with patient survival data from the Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases to facilitate personalized clinical treatment.
Article Snippet: The droplet microarray (DMA) slides were purchased from Aquarray GmbH (catalog, IR0050241542, Eggenstein‐Leopoldshafen, Germany).
Techniques: High Throughput Screening Assay, Drug discovery, Biomarker Discovery, Microarray, Western Blot, Mass Spectrometry